ThirtyFiveBio Limited
1 known investors
ThirtyFiveBio develops a therapeutic to protect the gut epithelium through GPR35 inhibition for patients with ulcerative colitis. The company targets an unmet need in inflammatory bowel disease treatment where current anti-inflammatory medicines have limited efficacy.